inpegsomatropin

Inpegsomatropin is a long-acting recombinant human growth hormone derivative. It is designed for the treatment of pediatric and adult patients with growth hormone deficiency (GHD). The molecule is a pegylated form of somatropin, allowing for sustained release and less frequent administration compared to daily growth hormone (GH) preparations. The pegylation process attaches polyethylene glycol (PEG) chains to the native somatropin, which prolongs its half-life and provides a steady-state concentration over time, enabling once-weekly dosing. Inpegsomatropin binds to the growth hormone receptor, stimulating growth and metabolic effects both directly and through increased production of insulin-like growth factor-1 (IGF-1). The drug aims to improve patient adherence, efficacy, and quality of life in GHD therapy. It is under development or has been developed by multiple biotechnology companies specializing in long-acting hormonal therapies.

Brand names

Yisheng

Other names

Somatropin (Xiamen Amoytop Biotech)Yipei growth hormone injection益佩生